# US 2017/0283831 A1 · Protected guide rnas (pgrnas)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283831 A1
- Document ID: US20170283831A1
- Status: Published application
- Kind: A1
- Application number: 15/620,098
- Filed: 2017-06-12
- Published: 2017-10-05
- Earliest claimed: 2014-12-12
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology; President and Fellows of Harvard College
- Applicants: The Broad Institute Inc.; Massachusetts Institute of Technology; President and Fellows of Harvard College
- Inventors: Feng Zhang; Omar O. Abudayyeh; James E. Dahlman; Patrick Hsu; David A. Scott
- Web page: https://patentgrep.com/patent/US20170283831A1

## CPC

- C12N 15/907: {in mammalian cells}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Y 301/21004: Type II site-specific deoxyribonuclease (3.1.21.4)
- A01K 2217/07: Animals genetically altered by homologous recombination
- A01K 2227/105: Murine
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems, wherein the guide sequence is modified by secondary structure to increase the specificity of the CRISPR-Cas system and whereby the secondary structure can protect against exonuclease activity and allow for 5′ additions to the guide sequence.

## Claims

### Claim 1

An engineered, non-naturally occurring composition comprising a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising a protected guide polynucleotide sequence comprising (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell and (b) a protector sequence that hybridizes to the guide sequence and comprises two or more nucleotides that are non-complementary to the target sequence, wherein the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises a Type II Cas9 protein complexed with the guide sequence that is hybridized to the target sequence.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the protected guide comprises a chimeric guide sequence and a tracr sequence, or wherein the protected guide comprises an engineered secondary structure.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the protected guide improves specificity of target binding as compared to the naturally occurring CRISPR-Cas system, or wherein the guide sequence is modified and the protected modified guide improves stability as compared to a naturally occurring CRISPR-Cas.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the protector sequence has a length between 3 and 120 nucleotides and comprises 3 or more contiguous nucleotides complementary to another sequence within the guide or protector and wherein the modification comprises or allows for hairpin formation, or wherein the guide sequence is 10-30 nucleotides long, or wherein the guide sequence comprises a protected sequence and an exposed sequence.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the exposed sequence is 1 to 19 nucleotides, or wherein the exposed sequence is at least 75%, at least 90% or about 100% complementary to the target sequence.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the guide sequence is at least 90% or about 100% complementary to the protector strand, or wherein the guide sequence is at least 75%, at least 90% or about 100% complementary to the target sequence.

### Claim 7 (depends on 1)

The composition of claim 1 further comprising a tracr mate sequence and a tracr sequence, wherein the tracr mate sequence is at least 75%, at least 90% or about 100% complementary to the tracr sequence, or wherein the composition further comprises an extension sequence.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the extension sequence is operably linked to the 5′ end of the protected guide sequence, and optionally directly linked to the 5′ end of the protected guide sequence, and/or wherein the extension sequence is 0-12 nucleotides.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the extension sequence is operably linked to the guide sequence at the 5′ end of the protected guide sequence and the 3′ end of the protector strand and optionally directly linked to the 5′ end of the protected guide sequence and the 3′ end of the protector strand, wherein the extension sequence is a linking sequence between the protected sequence and the protector strand; and/or wherein the extension sequence is 100% not complementary (0% complementary) to the protector strand, optionally at least 95%, at least 90%, at least 80%, at least 70%, at least 60%, or at least 50% not complementary to the protector strand.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the guide sequence further comprises mismatches appended to the end of the guide sequence, wherein the mismatches thermodynamically optimize specificity.

### Claim 11 (depends on 1)

A non-naturally occurring or engineered CRISPR-Cas complex composition comprising the protected guide of claim 1 and a CRISPR enzyme, wherein optionally the CRISPR enzyme comprises at least one mutation, such that the CRISPR enzyme has no more than 5% of the nuclease activity of the CRISPR enzyme not having the at least one mutation, and optionally comprising at least one or more nuclear localization sequences.

### Claim 12 (depends on 11)

The composition of claim 11 further comprising a non-naturally occurring or engineered composition comprising two or more adaptor proteins, wherein each protein is associated with one or more functional domains and wherein the adaptor protein binds to the distinct RNA sequence(s) inserted into the at least one loop of the protected guide; and/or wherein the CRISPR enzyme is associated with one or more functional domains.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the CRISPR enzyme has a diminished nuclease activity of at least 97%, or 100% as compared with the CRISPR enzyme not having the at least one mutation; and/or wherein the CRISPR enzyme comprises two or more mutations wherein two or more of D10, E762, H840, N854, N863, or D986 according to SpCas9 protein or any corresponding ortholog are mutated, or the CRISPR enzyme comprises at least one mutation wherein at least H840 is mutated.

### Claim 14 (depends on 13)

The composition of any one of claim 13, wherein the CRISPR enzyme comprises H840A, or D10A and H840A, or D10A and N863A, according to SpCas9 protein or any corresponding ortholog.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the one or more functional domains associated with the adaptor protein is a heterologous functional domain, or wherein the one or more functional domains associated with the CRISPR enzyme is a heterologous functional domain.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the adaptor protein is a fusion protein comprising the functional domain.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the one or more functional domains associated with the adaptor protein is a transcriptional activation domain, or wherein the one or more functional domains associated with the CRISPR enzyme is a transcriptional activation domain.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the one or more functional domains associated with the adaptor protein is a transcriptional activation domain comprising VP64, p65, MyoD1 or HSF1, or wherein the one or more functional domains associated with the CRISPR enzyme is a transcriptional activation domain comprises VP64, p65, MyoD1 or HSF1.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the one or more functional domains associated with the adaptor protein is a transcriptional repressor domain, or wherein the one or more functional domains associated with the CRISPR enzyme is a transcriptional repressor domain.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the transcriptional repressor domain is a KRAB domain, or wherein the transcriptional repressor domain is a SID domain or a SID4X domain.

### Claim 21 (depends on 12)

The composition of claim 12, wherein at least one of the one or more functional domains associated with the adaptor protein have one or more activities comprising methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, DNA cleavage activity or nucleic acid binding activity or wherein the one or more functional domains associated with the CRISPR enzyme have one or more activities comprising methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, DNA cleavage activity, nucleic acid binding activity, or molecular switch activity or chemical inducibility or light inducibility.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the DNA cleavage activity is due to a Fok1 nuclease.

### Claim 23 (depends on 12)

The composition of claim 12, wherein the one or more functional domains is attached to the CRISPR enzyme so that upon binding to the protected guide and target the functional domain is in a spatial orientation allowing for the functional domain to function in its attributed function.

### Claim 24 (depends on 12)

The composition of claim 12, wherein the protected guide is modified so that, after the protected guide binds the adaptor protein and further binds to the CRISPR enzyme and target, the functional domain is in a spatial orientation allowing for the functional domain to function in its attributed function.

### Claim 25 (depends on 12)

The composition of claim 12, wherein the one or more functional domains associated with the CRISPR enzyme is attached to the Rec1 domain, the Rec2 domain, the HNH domain, or the PI domain of the SpCas9 protein or any ortholog corresponding to these domains, or wherein the one or more functional domains associated with the CRISPR enzyme is attached to the Rec1 domain at position 553, Rec1 domain at 575, the Rec2 domain at any position of 175-306 or replacement thereof, the HNH domain at any position of 715-901 or replacement thereof, or the PI domain at position 1153 of the SpCas9 protein or any ortholog corresponding to these domains.

### Claim 26 (depends on 12)

The composition of claim 12, wherein the adaptor protein comprises MS2, PP7, Qβ, F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, Cb5, φCb8r, φCb12r, φCb23r, 7s or PRR1.

### Claim 27 (depends on 11)

The composition of claim 11 wherein the composition is in a cell or progeny thereof.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the cell is a eukaryotic cell or progeny thereof

### Claim 29 (depends on 28)

The composition of claim 28, wherein the eukaryotic cell is a mammalian cell or progeny thereof

### Claim 30 (depends on 29)

The composition of claim 29, wherein the mammalian cell is a human cell or progeny thereof.

### Claim 31 (depends on 12)

The composition of claim 12, wherein a first adaptor protein is associated with a p65 domain and a second adaptor protein is associated with a HSF1 domain.

### Claim 32 (depends on 11)

The composition of claim 11, wherein the composition comprises a CRISPR-Cas complex having at least three functional domains, at least one of which is associated with the CRISPR enzyme and at least two of which are associated with protected guide.

### Claim 33 (depends on 11)

A method for introducing a genomic locus event comprising the administration to a host or expression in a host in vivo of one or more of the compositions according to claim 11.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the genomic locus event comprises affecting gene activation, gene inhibition, or cleavage in the locus.

### Claim 35 (depends on 33)

The method according to claim 33, wherein the host is a eukaryotic cell or progeny thereof.

### Claim 36 (depends on 33)

The method according to claim 33, wherein the host is a mammalian cell or progeny thereof

### Claim 37 (depends on 33)

The method according to claim 33, wherein the host is a non-human eukaryote or progeny thereof.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the non-human eukaryote is a non-human mammal or progeny thereof.

### Claim 39 (depends on 37)

The method according to claim 37, wherein the non-human mammal is a mouse or progeny thereof.

### Claim 40 (depends on 11)

A method of modifying a genomic locus of interest to change gene expression in a cell or progeny thereof by introducing or expressing in a cell the composition of claim 11.

### Claim 41 (depends on 40)

The method according to claim 40 comprising the delivery of the composition or nucleic acid molecule(s) coding therefor, wherein said nucleic acid molecule(s) are operatively linked to regulatory sequence(s) and expressed in vivo.

### Claim 42 (depends on 41)

The method according to claim 41 wherein the expression in vivo is via a lentivirus, an adenovirus, or an AAV.

### Claim 43 (depends on 7)

The composition according to claim 7, wherein one or more of the extension sequence, the protector sequence, and the guide sequence comprise a chemically modified base.

### Claim 44 (depends on 1)

The composition according to claim 1, wherein the protector sequence is designed to have a binding free energy so that the overall free energy of the reaction is in a range of no more than +/−10% from zero, no more than +/−5% from zero, no more than +/−2% from zero, or zero.
